Clinical Trials Sponsored by Alnylam Pharmaceuticals Inc
Total 5021 results
-
Alnylam PharmaceuticalsRecruitingHypertension | High Cardiovascular RiskUnited States
-
Alnylam PharmaceuticalsRecruitingType 2 Diabetes Mellitus (T2DM)Canada
-
Alnylam PharmaceuticalsRecruitingEarly-Onset Alzheimer DiseaseUnited Kingdom, United States, Netherlands, Canada
-
Alnylam PharmaceuticalsRecruitingPrimary Hyperoxaluria Type 1France, Spain, United States, Israel, Belgium, Switzerland, Germany, United Kingdom, Italy, Canada
-
Alnylam PharmaceuticalsRecruitingTransthyretin-Mediated Amyloidosis | ATTR AmyloidosisIsrael, Italy, Netherlands, Spain, United States, France, Denmark, Germany, Portugal, Brazil, Taiwan
-
Alnylam PharmaceuticalsActive, not recruitingPrimary Hyperoxaluria Type 1 (PH1) | Primary HyperoxaluriaUnited States, France, United Kingdom, Israel, Germany
-
Alnylam PharmaceuticalsActive, not recruitingHypertensionUnited States, Canada, United Kingdom, Puerto Rico, Ukraine
-
Alnylam PharmaceuticalsCompletedAmyloidosisUnited States, Canada, Argentina, Australia, Bulgaria, Cyprus, Italy, Japan, Malaysia, Netherlands, Portugal, Spain, Sweden, Taiwan, United Kingdom, Germany, France, Korea, Republic of, Brazil, Mexico, Turkey
-
Alnylam PharmaceuticalsCompletedTTR-mediated AmyloidosisUnited States, United Kingdom
-
Alnylam PharmaceuticalsNo longer availableAcute Hepatic Porphyria
-
Alnylam PharmaceuticalsCompletedAmyloidosis, Familial | Transthyretin AmyloidosisFrance, Germany, Italy, Portugal, Spain, Sweden, United Kingdom
-
Alnylam PharmaceuticalsCompletedAcute Hepatic PorphyriaUnited States, Belgium, Bulgaria, France, Italy, Mexico, Spain, Taiwan, United Kingdom, Netherlands, Korea, Republic of, Switzerland, Czechia, Poland, Finland, Australia, Germany, Israel, Norway, South Africa
-
Alnylam PharmaceuticalsTerminatedZZ Type Alpha-1 Antitrypsin Deficiency Liver DiseaseUnited Kingdom
-
Alnylam PharmaceuticalsTerminatedAcute Hepatic Porphyria | Acute Intermittent Porphyria (AIP) | Hereditary Coproporphyria (HCP) | Variegate Porphyria (VP) | ALA Dehydratase Deficient Porphyria (ADP) | Hepatic Porphyrias | Porphyria AcuteUnited States
-
Alnylam PharmaceuticalsTerminatedAntitrypsin Deficiency Liver DiseaseUnited Kingdom
-
Alnylam PharmaceuticalsCompletedAmyloid Neuropathies | Amyloid Neuropathies, Familial | Amyloidosis, Hereditary | Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC) | Amyloidosis, Hereditary, Transthyretin-Related | Familial Transthyretin Cardiac AmyloidosisUnited States, France, Italy, Spain, Canada, Germany, Belgium, Sweden, United Kingdom
-
Alnylam PharmaceuticalsCompletedAcute Intermittent PorphyriaUnited States, United Kingdom, Sweden
-
Alnylam PharmaceuticalsCompleted
-
Alnylam PharmaceuticalsNot yet recruitingHereditary Amyloidosis, Transthyretin-Related | Asymptomatic Carrier StateFrance
-
Alnylam PharmaceuticalsRecruitingPolyneuropathy | Hereditary Transthyretin-mediated (hATTR) AmyloidosisNetherlands, Spain, United States, Germany, France, Italy, Portugal
-
Alnylam PharmaceuticalsRecruitingAcute Hepatic PorphyriaBelgium, France, Germany, United Kingdom, United States, Italy, Sweden
-
Alnylam PharmaceuticalsCompletedAcute Intermittent PorphyriaUnited States, United Kingdom, Sweden
-
Alnylam PharmaceuticalsActive, not recruitingTransthyretin Amyloidosis (ATTR) With CardiomyopathyUnited States, Australia, Brazil, Bulgaria, France, Italy, Japan, Mexico, Netherlands, Taiwan, United Kingdom, Belgium, Czechia, Denmark, New Zealand, Sweden, Korea, Republic of, Argentina, Chile, Hong Kong, Portugal
-
Alnylam PharmaceuticalsTerminatedNonalcoholic Steatohepatitis | NASHUnited States, Bulgaria, United Kingdom, Belgium, Turkey
-
Alnylam PharmaceuticalsActive, not recruitingTransthyretin Amyloidosis (ATTR) With CardiomyopathyUnited States, Poland, Argentina, Australia, Belgium, France, Germany, Japan, Netherlands, Portugal, Spain, Sweden, United Kingdom, Canada, Czechia, Denmark, Hungary, Ireland, Norway, Korea, Republic of, Austria, Croatia, Israel, Latvia, Lithuan... and more
-
Alnylam PharmaceuticalsTerminatedIgA Nephropathy (IgAN) | Berger Disease | Glomerulonephritis, IgACanada, Malaysia, France, Sweden, United Kingdom, Philippines, Singapore, Spain, Taiwan
-
Alnylam PharmaceuticalsTerminatedRecurrent Calcium Oxalate Kidney Stone Disease | Elevated Urinary Oxalate LevelsUnited States, Italy, Spain, Belgium, Switzerland, United Kingdom
-
Alnylam PharmaceuticalsCompletedPrimary Hyperoxaluria | PH1 | RNAi Therapeutic | siRNA | AGTFrance, United Kingdom, Netherlands, Israel, Germany
-
Alnylam PharmaceuticalsCompleted
-
Alnylam PharmaceuticalsNo longer availableAmyloid Neuropathies | Amyloid Neuropathies, Familial | TTR-mediated Amyloidosis | Amyloidosis, Hereditary | Amyloidosis, Hereditary, Transthyretin-Related | Familial Amyloid Polyneuropathies
-
Alnylam PharmaceuticalsCompletedAcute Hepatic Porphyria | Acute Intermittent Porphyria | Porphyria, Acute Intermittent | Acute Porphyria | Hereditary Coproporphyria (HCP) | Variegate Porphyria (VP) | ALA Dehydratase Deficient Porphyria (ADP)United States, Spain, United Kingdom, Korea, Republic of, Australia, Bulgaria, Canada, Denmark, Finland, France, Germany, Italy, Japan, Mexico, Netherlands, Poland, Sweden, Taiwan
-
Alnylam PharmaceuticalsCompletedTTR-mediated AmyloidosisUnited States, Canada, United Kingdom
-
Alnylam PharmaceuticalsCompletedParoxysmal Nocturnal Hemoglobinuria (PNH)Spain, United Kingdom
-
Alnylam PharmaceuticalsCompletedPrimary Hyperoxaluria Type 1 (PH1)France, United Kingdom, Netherlands, Israel, Germany
-
Alnylam PharmaceuticalsCompletedPorphyria, Acute Intermittent | Acute Intermittent Porphyria (AIP) | Acute Hepatic Porphyria (AHP) | Acute PorphyriaSweden
-
Alnylam PharmaceuticalsCompletedTTR-mediated AmyloidosisPortugal, Sweden, Brazil, United States, France, Spain, Germany
-
Alnylam PharmaceuticalsTerminatedHepatitis B | Chronic Hepatitis B | Hepatitis B, Chronic | HBV | Hepatitis B InfectionUnited Kingdom, New Zealand, Singapore, Korea, Republic of, Australia, Hong Kong
-
Alnylam PharmaceuticalsCompletedA Study of the Safety, Tolerability and Pharmacokinetics of ALN-TTR02 in Japanese Healthy VolunteersTransthyretin (TTR)-Mediated AmyloidosisUnited Kingdom
-
Alnylam PharmaceuticalsCompletedRespiratory Syncytial Virus InfectionsUnited States
-
Alnylam PharmaceuticalsRecruitingTransthyretin-Mediated AmyloidosisUnited Kingdom
-
Alnylam PharmaceuticalsActive, not recruitingHypertensionUnited States, Canada, Latvia, Poland, United Kingdom, Germany, Lithuania, Estonia, Puerto Rico
-
Alnylam PharmaceuticalsTerminated
-
Alnylam PharmaceuticalsActive, not recruitingTransthyretin Amyloidosis | Amyloidosis, HereditaryUnited States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Cyprus, France, Germany, Greece, Italy, Japan, Korea, Republic of, Malaysia, Mexico, Netherlands, Portugal, Spain, Sweden, Taiwan, United Kingdom
-
Alnylam PharmaceuticalsActive, not recruitingPrimary Hyperoxaluria Type 1 | Primary HyperoxaluriaUnited States, Italy, France, Lebanon, Belgium, Netherlands, Israel, United Arab Emirates, Australia, Jordan, Turkey
-
Alnylam PharmaceuticalsNo longer availableTransthyretin-mediated Amyloidosis With Cardiomyopathy | ATTR Amyloidosis With CardiomyopathyUnited States
-
Alnylam PharmaceuticalsCompletedPrimary Hyperoxaluria Type 1 (PH1)United States, France, United Kingdom, Switzerland, Netherlands, Israel, Germany, United Arab Emirates
-
Alnylam PharmaceuticalsApproved for marketingPrimary HyperoxaluriaBelgium
-
Alnylam PharmaceuticalsCompletedPolyneuropathy | Hereditary Transthyretin-mediated (ATTRv) AmyloidosisUnited States
-
Alnylam PharmaceuticalsTerminatedAmyloidosis | Leukocyte Chemotactic Factor 2 AmyloidosisUnited States, Malaysia, United Kingdom, Mexico, Egypt, India
-
Alnylam PharmaceuticalsCompletedATTR Amyloidosis | Transthyretin (TTR)-Mediated Amyloidosis | Familial Amyloidotic Polyneuropathy (FAP) | Familial Amyloid NeuropathiesFrance, Germany, Portugal, United Kingdom, Sweden, Spain